Skip to content

Haemonetics HAE Other intangible assets—net

Other intangible assets—net at other companies

TFX
TeleflexTFX
$1.49B-33.3%
Boston Scientific logo
Boston ScientificBSX
$7.06B+7.5%
LivaNova logo
LivaNovaLIVN
$224.56M-5.1%
ICU Medical logo
ICU MedicalICUI
$598.97M-16.4%
Abbott logo
AbbottABT
Medtronic logo
MedtronicMDT

Other financials

Income statement

See full
Revenue$346.4M+4.8%
Gross profit$198.2M+2.7%
Operating income$67.4M+14.2%
Net income$44.7M+19.3%
EPS (diluted)$0.95+28.4%

Balance sheet

See full
Cash & equivalents$245.4M-20.0%
Total debt$1.3B-0.7%
Total equity$796.3M-3.0%
Total assets$2.4B-2.2%

Cash flow

See full
Operating cash flow$70.9M-39.1%
CapEx$17.7M+12.9%
Free cash flow$53.3M-47.2%

Valuation

See full
Market cap$3.31B-18.0%

Profitability

See full
Gross margin59%+4.0pp
Operating margin19%+5.9pp
Net margin13.3%+3.8pp
FCF margin19.5%+9.1pp

Returns & leverage

See full
Return on equity19.3%+5.2pp
Debt / equity1.6×0.0×
Current ratio+1.3×

Where this comes from

Reported directly by Haemonetics in its filing.

Tagged under the XBRL concept us-gaap:IntangibleAssetsNetExcludingGoodwill.

The official record: Haemonetics’s 10-K, filed May 20, 2026, on SEC EDGAR. View the filing →

Ask your AI about Haemonetics's other intangible assets—net.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Haemonetics's other intangible assets—net?
Haemonetics (HAE) reported other intangible assets—net of $447.66M in Q1 2026.
How has Haemonetics's other intangible assets—net changed year-over-year?
Haemonetics's other intangible assets—net decreased by 1.8% year-over-year, from $455.74M to $447.66M.
What is the long-term trend for Haemonetics's other intangible assets—net?
Over 5 years (2021 to 2026), Haemonetics's other intangible assets—net has grown at a 4.1% compound annual growth rate (CAGR), from $365.48M to $447.66M.
What does other intangible assets—net mean?
This represents the net book value of identifiable non-physical assets such as patents, intellectual property, software licenses, and trademarks, excluding goodwill. These assets are vital for companies relying on proprietary technology and R&D. It captures the value of the company's competitive moat derived from its intellectual property portfolio.